RxDoctor Payments Data

Rajesh Shah, MD

Internal Medicine · Belle Vernon, PANPI 1508821877

Payments from drug & device makers

$334in general payments, 2019–2025

Across 20 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$151
  • AbbVie$49
  • GSK$29
  • Abbott$24
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$21
  • Novo Nordisk$18
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$32096%
  • Education$154%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$334 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$50,769
Medicare patients
118
Services billed
571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban321$250,417
RybelsusSemaglutide116$147,046
JardianceEmpagliflozin62$68,376
OzempicSemaglutide54$59,957
XareltoRivaroxaban61$56,255
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$43,447
EntrestoSacubitril/Valsartan30$26,012
FarxigaDapagliflozin Propanediol31$25,176
Breo ElliptaFluticasone/Vilanterol37$18,070
TradjentaLinagliptin19$17,177
BrilintaTicagrelor28$13,227
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$12,156
JanuviaSitagliptin Phosphate22$10,686
Albuterol Sulfate HfaAlbuterol Sulfate211$10,604
Spiriva RespimatTiotropium Bromide14$10,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$151$250,417321 claims
Novo NordiskRybelsus, Ozempic$18$207,003170 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$15$96,09795 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$29$73,673102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Belle Vernon

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →